Obesity Clinical Trial
— ProteinOfficial title:
The Contribution of Gastrointestinal Appetite Hormones to Protein-induced
Dietary protein appears to be the most satiating and thermogenic macronutrient. However, how
protein exerts its effect on appetite is not fully known. The effect have been suggested to
be related to a higher oxidation rate of protein compared to carbohydrate and fat, and also
to a greater thermogenic effect causing greater increase in core temperature. The
involvement of peripheral appetite-regulating hormones has only been sparingly investigated.
The objective is to investigate the satiating effects of meals with varying content of
meat-based protein and whether a dose-response effect can be found on appetite-regulating
hormones and appetite ratings.
Design: 25 men will participate in the 3-way, randomized, double-blind, crossover study. The
test meals is isocaloric with 30E% fat and increasing protein content at the expense of
carbohydrate. Test meals are: normal protein content (NP, 14E% protein), medium-high protein
content (MHP, 25E%), and high protein content(HP, 50E%). Four-hour subjective appetite
ratings and blood samples will be assessed every half-hour. Subsequently, the subjects will
served an ad libitum lunch.
| Status | Completed |
| Enrollment | 25 |
| Est. completion date | July 2008 |
| Est. primary completion date | July 2008 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Male |
| Age group | 18 Years to 50 Years |
| Eligibility |
Inclusion Criteria: - Healthy, - BMI: 18.5-40 kg/m2, - Weight stable (within +/- 3 kg) two months prior to study inclusion, - Non-smoking, - Nonathletic, Exclusion Criteria: - BMI > 40 kg/m2, - Change in smoking status, - Daily or frequent use of medication, - Suffering from metabolic diseases, - Suffering from psychiatric diseases, - Suffering from any other clinical condition, which would make the subject unfit to participate in the study, - Blood pressure was above 150/90 mmHg, - Hemoglobin < 8 mmol/l. |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Department of human Nutrition | Frederiksberg |
| Lead Sponsor | Collaborator |
|---|---|
| University of Copenhagen |
Denmark,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Acute 4-h changes from baseline in the postprandial concentration of GLP-1 | Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 30, 60, 90, 120, 150, 180, 240 minutes. Blood samples are analyzed for GLP-1. Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed. |
Measured on 3 seperate test days in a crossover design. Each test day was seperated by >4 weeks. On each test day GLP-1 was measured prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 240 minutes post intake | No |
| Secondary | Acute 4-h changes from baseline in subjective appetite sensations using visual analogue scales | Assessment of subjective appetite sensations (visual analogue scales (VAS)) at time 0 (baseline - prior to the test meal) and at time 30, 60, 90, 120, 150, 180, 210, 240 minutes post intake. Measured subjective appetite sensations of hunger, satiety, prospective consumption, fullness, composite appetite score and sensory desires to something sweet, salty, rich in fat, or meat/fish. Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed. |
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day appetite sensations were measured prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 210, 240 minutes post intake. | No |
| Secondary | Acute 4-h changes from baseline in the postprandial concentration of appetite regulating hormones/peptides | Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 30, 60, 90, 120, 150, 180, 240 minutes. Blood samples are or will be analyzed for glucagon, pancreatic polypeptide (PP), glucose-dependent insulinotropic polypeptide (GIP), peptid YY (PYY), ghrelin, CCK, amylin and apolipoprotein-IV. Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed. |
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day blood samples were collected prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 240 minutes post intake. | No |
| Secondary | Acute 4-h changes from baseline in the postprandial concentration of glucose | Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes. Blood samples was analyzed for glucose. Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed |
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day blood samples were collected prior to the test meal (time 0) and 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes post intake. | No |
| Secondary | Acute 4-h changes from baseline in the postprandial concentration of insulin | Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes. Blood samples was analyzed for insulin. Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed |
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day blood samples were collected prior to the test meal (time 0) and 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes post intake. | No |
| Secondary | Acute 4-h changes from baseline in the postprandial concentrations of lipids | Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 30, 60, 90, 120, 150, 180, 240 minutes. Blood samples were analyzed for triglycerides, free fatty acids (FFA), total cholesterol, HDL-cholesterol. The concentration of low density lipoprotein (LDL) cholesterol will be estimated as described by Friedwald et al. Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed |
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day blood samples were collected prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 240 minutes post intake. | No |
| Secondary | Acute 4-h changes from baseline in the body temperature | Body temperature measurement were assessed at time 0, 30, 60, 90, 120, 150, 180, 210, 240 minutes post intake. Temperature was measured in the participants' ears (ThermoScan 6022, Braun GmbH, Kronberg, Germany). Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed |
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day temperature was measured prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 210, 240 minutes post intake. | No |
| Secondary | Rate of gastric emptying (4-h change from baseline in postprandial concentration of paracetamol) | The subjects drank 500 mg paracetamol desolved in 100 ml water together with the test meal. Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 30, 60, 90, 120, 150, 180, 240 minutes. Blood samples was analyzed for concentration of paracetamol. Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed. |
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day blood samples were collected prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 240 minutes post intake. | No |
| Secondary | Rating of the organoleptic quality of the test meals | After completion of the meal the subjects rated the organoleptic quality of the meal by visual analogue scales (VAS) in regard to appearance, smell, taste, after-taste, and general palatability of the meal. | Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day after completion of the test meal (approximately) time 15 minutes post intake) subjects rated the test meals | No |
| Secondary | Rating of the organoleptic quality of the ad libitum meal | After completion of the meal the subjects rated the organoleptic quality of the ad libitum meal by visual analogue scales (VAS) in regard to appearance, smell, taste, after-taste, and general palatability of the meal. | Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day after completion of the ad libitum meal subjects rated the meal | No |
| Secondary | Subjective appetite sensations (visual analogue scales) after ad libitum meal | After completion of the meal the subjects rated the subjective appetite sensations by visual analogue scales (VAS) in regard to sensation of hunger, satiety, prospective consumption, fullness, composite appetite score and sensory desires to eat something sweet, salty, rich in fat, or meat/fish. | Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day after completion of the ad libitum meal subjects rated their subjective sensation of appetite (approximately 4.5-h post intake of the test meal) | No |
| Secondary | ad libitum energy intake (EI) | 240 min after each test meal an ad libitum meal was served, and the total energy intake was recorded | Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. EI was measured 240 min after intake of the test meal | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |